NAD+ (Nicotinamide Adenine Dinucleotide): Research Overview

Published: May 2026

Nicotinamide adenine dinucleotide (NAD+) is a pyridine dinucleotide coenzyme present in every living cell, first described by Arthur Harden and William Young in 1906 as a heat-stable “cozymase” required for yeast fermentation. It is not a peptide. The molecule is built from two nucleotides joined tail to tail through a pair of bridging phosphates: an adenine-bearing nucleotide and a nicotinamide-bearing nucleotide. NAD+ carries CAS number 53-84-9, the molecular formula C₂₁H₂₇N₇O₁₄P₂, and a molecular weight of approximately 663.43 g/mol. The nicotinamide ring accepts a hydride ion to form the reduced species NADH, and this reversible NAD+/NADH cycling makes the coenzyme the central electron carrier of cellular metabolism. Beyond its redox role, NAD+ is consumed as a substrate by sirtuins, poly(ADP-ribose) polymerases, and CD38, which links the molecule to a wide preclinical literature on aging, mitochondrial function, and axonal biology.

Molecular Profile

White Market Peptides offers research-grade NAD+ (1000 mg) at a 99%+ purity standard, third-party tested for identity and purity. View its Certificate of Analysis (PDF) ↗

Redox Biochemistry and Energy Metabolism

The defining property of NAD+ in metabolism is its ability to shuttle electrons. The oxidized form accepts a hydride from substrates during glycolysis, the citric acid cycle, and fatty acid oxidation, becoming NADH, which then donates those electrons to complex I of the mitochondrial electron transport chain to drive ATP synthesis. Because the total cellular pool of the coenzyme is finite, the ratio of NAD+ to NADH functions as a readout of metabolic state, with a high ratio signaling an oxidized, energy-demanding condition. This stoichiometric coupling is why the cofactor sits at the center of preclinical studies on bioenergetics.

NAD+ also exists alongside its phosphorylated counterpart NADP+, which operates largely in reductive biosynthesis and antioxidant defense. The compartmentalization of these pools between the cytosol, mitochondria, and nucleus has been examined in cell-based research using genetically encoded biosensors, work that established that distinct subcellular NAD+ pools are maintained and regulated independently. Verdin (2015) reviewed in Science how this redox chemistry intersects with the signaling functions of the coenzyme, framing NAD+ as both a metabolic cofactor and a consumed substrate for regulatory enzymes.

Sirtuins as NAD+-Dependent Deacetylases

A turning point in NAD+ biology came when the silencing protein Sir2 was shown to require the coenzyme for catalytic activity. Imai et al. (2000) reported in Nature that Sir2 is an NAD-dependent histone deacetylase, cleaving NAD+ during the removal of acetyl groups from lysine residues and releasing nicotinamide and O-acetyl-ADP-ribose as products. This finding connected the cellular energy state, reported by NAD+ availability, directly to chromatin regulation and transcriptional silencing, and it grounded earlier genetic observations linking Sir2 to replicative lifespan in yeast.

The mammalian sirtuin family (SIRT1 through SIRT7) extended this enzymology across the cytosol, nucleus, and mitochondria. Because each deacetylation reaction consumes one molecule of NAD+, sirtuin activity is sensitive to fluctuations in the coenzyme pool, a dependence that has made sirtuins a recurring focus of preclinical research on metabolic stress and caloric restriction. Yoshino, Baur, and Imai (2018) summarized in Cell Metabolism how NAD+ availability constrains sirtuin signaling and how the intermediates that feed the biosynthetic pathway have been studied as a means of altering that availability in animal and cell models.

PARP Enzymes and the DNA Damage Response

Poly(ADP-ribose) polymerases (PARPs) are a second major class of NAD+-consuming enzymes. When DNA strand breaks occur, PARP-1 is recruited to the lesion and catalyzes the transfer of ADP-ribose units from NAD+ onto target proteins, building branched poly(ADP-ribose) chains that recruit repair machinery to the damage site. Each cycle of this reaction draws down the cellular NAD+ pool, and intense genotoxic stress can deplete the coenzyme substantially in cultured cells.

This consumption places PARP activity in competition with sirtuins for a shared substrate, a relationship that has been examined extensively in preclinical metabolic models. Verdin (2015) discussed in Science how the demand from PARPs during the DNA damage response can lower NAD+ availability for other enzymes, treating the coenzyme as a finite resource that multiple enzyme families draw upon. Research in this area has used PARP inhibition in animal and cellular systems as a tool to probe how NAD+ flux is partitioned among competing consumers.

CD38 and Age-Associated NAD+ Decline

Tissue NAD+ concentrations decline with age across multiple species in preclinical measurements, and the glycohydrolase CD38 has been identified as a principal driver of that decline. Camacho-Pereira et al. (2016) reported in Cell Metabolism that CD38 expression increases in several tissues during aging in mice and that this rise correlates with falling NAD+ levels and mitochondrial dysfunction. The authors showed that the effect operates through a SIRT3-dependent mechanism, linking CD38 activity to impaired mitochondrial function in aged animals.

CD38 degrades NAD+ and its precursor nicotinamide mononucleotide, positioning the enzyme as a regulator of precursor availability as well as the coenzyme pool itself. Studies in CD38-knockout mice demonstrated preserved NAD+ levels and protection against age-related metabolic changes, observations that have made CD38 a frequent target in preclinical investigations of NAD+ homeostasis. These findings tied the age-dependent fall in the coenzyme to a specific enzymatic source, the rising activity of CD38.

NAD+ Precursors and Mitochondrial Studies in Aged Mice

The observation that NAD+ falls with age prompted research into whether supplying biosynthetic intermediates could restore the pool in animal models. Cantó et al. (2012) reported in Cell Metabolism that the precursor nicotinamide riboside raised NAD+ levels, activated sirtuin signaling, increased oxidative metabolism, and protected mice against high-fat-diet-induced obesity, demonstrating that dietary precursors can shift NAD+ flux and downstream mitochondrial activity in vivo.

Mills et al. (2016) extended this line of work in Cell Metabolism by administering nicotinamide mononucleotide to mice over twelve months, reporting that long-term precursor administration mitigated several age-associated physiological changes, including alterations in energy metabolism and mitochondrial function, without overt toxicity in the study cohort. Gomes et al. (2013) had earlier described in Cell a pseudohypoxic state arising from declining NAD+ that disrupted communication between the nuclear and mitochondrial genomes during aging, and reported that raising NAD+ in aged mice reversed this specific signature in skeletal muscle. Together these animal studies established NAD+ precursors as research tools for probing the mitochondrial consequences of coenzyme depletion.

Looking to source this compound? NAD+ (1000 mg) is available for laboratory research, with documented batch testing. View its Certificate of Analysis (PDF) ↗

NAD+ in Axonal Degeneration and Neurodegeneration Research

A distinct research thread connects NAD+ metabolism to the survival of axons. After an axon is severed, a programmed self-destruction process known as Wallerian degeneration proceeds, and the local collapse of NAD+ is an early event in that program. Essuman et al. (2017) reported in Neuron that the protein SARM1 possesses intrinsic NAD+ cleavage activity within its Toll/Interleukin-1 receptor domain, identifying the enzyme that actively destroys the axonal NAD+ pool and showing that this catalytic activity promotes pathological axonal degeneration in cellular and animal models.

This discovery reframed SARM1 from a signaling adaptor into a metabolic enzyme whose activation triggers axon loss, and it placed NAD+ depletion at the mechanistic center of the degeneration program. Verdin (2015) had reviewed in Science the broader connections between NAD+ metabolism, aging, and neurodegeneration, noting that the coenzyme links cellular energy status to neuronal maintenance. Preclinical work in this area has used SARM1 manipulation to test whether preserving axonal NAD+ alters the course of degeneration in injury and disease models.

Key Published References

1. Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 2000;403(6771):795-800. PMID: 10693811
2. Cantó C, Houtkooper RH, Pirinen E, et al. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab. 2012;15(6):838-847. PMID: 22682224
3. Gomes AP, Price NL, Ling AJY, et al. Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. 2013;155(7):1624-1638. PMID: 24360282
4. Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science. 2015;350(6265):1208-1213. PMID: 26785480
5. Camacho-Pereira J, Tarragó MG, Chini CCS, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metab. 2016;23(6):1127-1139. PMID: 27304511
6. Mills KF, Yoshida S, Stein LR, et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab. 2016;24(6):795-806. PMID: 28068222
7. Essuman K, Summers DW, Sasaki Y, Mao X, DiAntonio A, Milbrandt J. The SARM1 Toll/Interleukin-1 receptor domain possesses intrinsic NAD+ cleavage activity that promotes pathological axonal degeneration. Neuron. 2017;93(6):1334-1343. PMID: 28334607
8. Yoshino J, Baur JA, Imai SI. NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metab. 2018;27(3):513-528. PMID: 29249689

Product Availability

NAD+ is available for qualified research applications through White Market Peptides: NAD+ 1000 mg: Research Grade.